Bermekimab

贝迈奇单抗

Report date: 2023/04/07 17:51:59

Base Information

Drug NameBermekimab
Drug Alias NameHuman IGG1 monoclonal antibody specific for human interleukin-1 alphaHutruoXilonixT2-18C3RA-18C3 +[11] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionInterleukin-1 alpha inhibitors
TargetsInterleukin-1 alpha
Therapy Area/IndicationsDiabetes Mellitus, Type 2PsoriasisPyoderma Gangrenosum +[12] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumCanada +[20] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaDiscontinued
Originator CompaniesXbiotech Inc
China Registration ClassN/A

Develop Information

Active CompaniesHellenic Institute For The Study Of SepsisJanssen Research & Development Llc
Inactive CompaniesJohnson & Johnson (China) Investment LtdCatalent Pharma SolutionsXbiotech Germany Gmbh +[4] 
Active IndicationsScleroderma, Systemic
Inactive IndicationsDiabetes Mellitus, Type 2PsoriasisPyoderma Gangrenosum +[11] 

Other Information

ATC CodeL01XC29
Related LinksWikipediaDrugBankKEGG